Abstract: Methods and apparatuses to define an insertion indicator on a Braille device are described. Information about an insertion indicator at a location on a display device is received. An output associated with the insertion indicator is provided to a Braille device. The output to the Braille device reproduces the location of the insertion indicator on the display device. The output associated with the insertion indicator may be provided to at least two cells of the Braille device. The output to the Braille device may be provided to raise a first dot of a first Braille cell on the Braille device, wherein the first Braille cell corresponds to a second location that precedes the first location on the display device. A Braille caption panel may be displayed on a display device, the Braille caption panel includes a simulation of the output associated with the insertion indicator on the Braille device.

Abstract: Methods and apparatuses to provide improved Braille support are described herein. A connection to a Braille device is received, and a Braille caption panel that includes a Braille code is displayed to simulate an output to the Braille device. The Braille caption panel can include a text translated to the Braille code. The Braille caption panel can include a control element. An accessibility service can be automatically launched to provide the output to the Braille device.

Abstract: The present invention is directed to a combination treatment of an opioid antagonist e.g., naltrexone and a second compound selected from the group consisting of a GABA B agonist, an NMDA antagonist, a serotonin antagonist, and a cannabinoid antagonist is the key to the successful treatment of a brain reward system disorder. A brain reward system, include but are not limited, to pathological gambling, compulsive alcohol consumption, compulsive over-eating and obesity, compulsive smoking, and drug addiction. The compounds and methods of the present invention effectively reduce the cravings, withdrawal symptoms and negative drug side effects associated with a monotherapy. As such, patient compliance is greatly increased, thereby decreasing relapse of a brain reward system disorder.